Table 4.
Mammaprint-trained results stratified by other test results, trinary classification.
| Mammaprint-trained first | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mammaprint-trained low risk | Mammaprint-trained high risk | |||||||||||||||||
| HR (95% CI) | DMFS (95% CI) | P* (N) | HR (95% CI) | DMFS (95% CI) | P (N) | |||||||||||||
| All cases | REF |
86.9 (85.1–88.4) |
<0.001 (2180) |
2.64 (2.22–3.14) |
70.7 (67.6–73.6) |
<0.001 (1104) |
||||||||||||
| N-Ch− | REF |
93.5 (90.5–95.6) |
<0.001 (599) |
4.23 (2.72–6.56) |
78.2 (73.0–82.5) |
<0.001 (371) |
||||||||||||
| N+Ch− | REF |
85.9 (83.1–88.3) |
<0.001 (896) |
3.34 (2.56–4.36) |
62.4 (56.5–67.7) |
<0.001 (351) |
||||||||||||
| Ch+ | REF |
82.3 (78.8–85.3) |
<0.001 (681) |
1.86 (1.41–2.46) |
71.2 (65.8–75.9) |
<0.001 (379) |
||||||||||||
| Oncotype-trained low | Oncotype-trained Int | Oncotype-trained high | Oncotype-trained low | Oncotype-trained Int | Oncotype-trained high | |||||||||||||
| HR | DMFS | P* | HR | DMFS | P | HR | DMFS | P | HR | DMFS | P* | HR | DMFS | P | HR | DMFS | P | |
| All cases | REF |
89.1 (87.1–90.8) |
<0.001 (1483) |
1.74 (1.33–2.28) |
83.2 (79.6–86.1) |
<0.001 (645) |
3.22 (1.82–5.69) |
70.4 (53.7–82.1) |
<0.001 (52) |
REF |
72.1 (60.9–80.6) |
0.031 (124) |
1.10 (0.72–1.68) |
73.2 (68.8–77.2) |
0.668 (528) |
1.47 (0.97–2.24) |
67.1 (62.2–71.6) |
0.072 (452) |
| N−Ch− | REF |
93.8 (90.0–96.2) |
0.485 (407) |
1.35 (0.62–2.92) |
92.2 (85.6–95.8) |
0.452 (174) |
NA | 100 |
NA (18) |
REF |
80.8 (62.8–90.7) |
0.196 (51) |
1.12 (0.49–2.56) |
80.8 (73.2–86.4) |
0.784 (175) |
1.68 (0.74–3.80) |
74.0 (65.0–81.0) |
0.212 (145) |
| N+Ch− | REF |
87.7 (84.4–90.3) |
<0.001 (639) |
1.49 (0.98–2.29) |
84.2 (78.2–88.7) |
0.064 (237) |
5.14 (2.46–10.7) |
54.2 (28.0–74.5) |
<0.001 (20) |
REF |
67.6 (48.0–81.2) |
0.047 (44) |
1.22 (0.63–2.35) |
66.9 (58.3–74.1) |
0.552 (166) |
1.83 (0.96–3.49) |
55.3 (46.0–63.6) |
0.067 (141) |
| Ch+ | REF |
86.8 (82.6–90.0) |
<0.001 (434) |
2.05 (1.38–3.06) |
75.8 (69.1–81.2) |
<0.001 (233) |
3.52 (1.40–8.86) |
61.1 (29.8–81.9) |
0.007 (14) |
REF |
64.2 (37.6–81.8) |
0.903 (29) |
0.85 (0.40–1.81) |
71.2 (63.0–77.9) |
0.676 (185) |
0.90 (0.42–1.92) |
71.9 (63.8–78.4) |
0.792 (165) |
| Prosigna-trained low | Prosigna-trained Int | Prosigna-trained high | Prosigna-trained low | Prosigna-trained Int | Prosigna-trained high | |||||||||||||
| HR | DMFS | P* | HR | DMFS | P | HR | DMFS | P | HR | DMFS | P* | HR | DMFS | P | HR | DMFS | P | |
| All cases | REF |
92.2 (89.8–94.0) |
<0.001 (814) |
1.77 (1.27–2.46) |
86.1 (83.3–88.5) |
0.001 (944) |
3.01 (2.11–4.28) |
78.1 (73.0–82.3) |
<0.001 (422) |
REF |
90.0 (47.3–98.5) |
0.006 (12) |
2.17 (0.30–15.8) |
79.4 (72.6–84.7) |
0.446 (211) |
3.57 (0.50–25.5) |
68.4 (64.9–71.7) |
0.204 (881) |
| N−Ch− | REF |
96.6 (91.8–98.6) |
0.069 (217) |
2.24 (0.80–6.28) |
93.1 (88.1–96.0) |
0.126 (249) |
3.37 (1.15–9.86) |
89.6 (80.6-94.5) |
0.027 (133) |
REF | 100 |
0.222 (3) |
NA |
83.8 (70.2-91.5) |
NA (72) |
NA |
76.5 (70.6–81.4) |
NA (296) |
| N+Ch− | REF |
90.0 (85.7–93.1) |
<0.001 (315) |
1.28 (0.79–2.06) |
86.6 (82.2–90.0) |
0.315 (415) |
2.65 (1.59–4.42) |
75.7 (66.8–82.5) |
<0.001 (166) |
REF | 100 |
0.002 (3) |
NA |
83.6 (70.7–91.1) |
NA (61) |
NA |
57.4 (50.8–63.5) |
NA (287) |
| Ch+ | REF |
91.1 (86.5–94.2) |
<0.001 (281) |
2.42 (1.45–4.03) |
79.3 (73.3–84.2) |
0.001 (278) |
3.91 (2.26–6.79) |
69.0 (58.8–77.2) |
<0.001 (122) |
REF |
75.0 (12.8–96.1) |
0.951 (6) |
1.38 (0.19–10.3) |
72.7 (60.8–81.5) |
0.752 (78) |
1.37 (0.19–9.83) |
70.9 (64.7–76.2) |
0.756 (295) |
HR = hazard ratio, 95%CI = 95% confidence interval. P* = p value of log-rank test to compare survival distributions. REF = reference group. P = p value of Wald test for comparison versus reference (low risk) group. DMFS = distant metastasis free survival at 10 years (see text). (N) = number of cases in subgroups. All cases = all ER+ve/HER2-ve cases. N−Ch− = node negative cases treated without chemotherapy. N+Ch− = Node positive cases treated without chemotherapy. Ch+ = cases treated with chemotherapy (node negative and node positive combined). Int = intermediate.